The cardiac electrophysiology team at NewYork-Presbyterian Queens has performed the first U.S. procedure using a new artificial intelligence software system, designed to improve cardiac ablation in people with advanced atrial fibrillation, an irregular and often very rapid heart rhythm (arrhythmia) that can lead to blood clots in the heart.

Columbia University is one of the leading programs in the United States conducting a groundbreaking Phase 2 clinical trial of an investigational gene therapy for dry age-related macular degeneration.

NewYork-Presbyterian obstetricians and gynecologists continue to investigate COVID-19 and its potential impact on pregnancy outcomes, including studies on serial testing for SARS-CoV-2 and vaccinations.

The latest advance in radiation therapy—using AI to adjust treatments on the fly—is now available for select cancer patients at NewYork-Presbyterian/Columbia University Irving Medical Center.

A simple surgical technique during cardiac surgery was associated with a 56 percent reduction in the incidence of an irregular heart rhythm known as atrial fibrillation that can lead to stroke, with no added risks or side effects.

NewYork-Presbyterian, one of the nation’s most comprehensive, integrated academic healthcare systems, today launched “Stay Amazing,” its first new brand platform and campaign in more than a decade.

Columbia University Irving Medical Center with NewYork-Presbyterian has been named a Center of Excellence by the National Organization for Rare Disorders (NORD) and joins a national network dedicated to improving treatment and care for people with rare diseases.

It is estimated that nearly 3.4 million Americans are currently diagnosed with epilepsy; 470,000 are children ages 14 and younger.